Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Expands with Advanced Biomarker & Imaging Tools | Allergan plc., Pfizer Inc, Gilead Sciences, Inc., Genfit SA

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market is valued at a significant CAGR during the forecast period (2024-2031). As per DataM Intelligence Database.

Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics focus on managing liver inflammation and fibrosis caused by fat accumulation. Diagnostic tools include imaging, liver biopsy, and biomarker assays. Current treatments target metabolic pathways, insulin resistance, and inflammation. Drugs under development include FXR agonists, PPAR modulators, and anti-fibrotic agents. Lifestyle changes remain the cornerstone of therapy. Early detection is vital to prevent progression to cirrhosis or liver cancer.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Landscape:- https://datamintelligence.com/download-sample/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?Ranjith

☛ Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In July 2025, Intercept Pharmaceuticals reported positive Phase 3 results for Ocaliva (obeticholic acid) in patients with NASH and advanced fibrosis, demonstrating improved liver histology and reduced progression to cirrhosis.

✅ In June 2025, Genfit advanced its elafibranor program into late-stage clinical trials, targeting metabolic modulation and inflammation reduction in NASH patients.

✅ In May 2025, Gilead Sciences launched non-invasive diagnostic imaging tools for NASH, enabling earlier detection of liver fibrosis and monitoring of therapeutic efficacy.

Japan: Recent Industry Developments

✅ In July 2025, Daiichi Sankyo initiated clinical trials for a novel dual-action therapy targeting both liver fat accumulation and inflammation in Japanese NASH patients.

✅ In June 2025, Takeda Pharmaceutical developed biomarker-based diagnostic kits for early NASH detection, focusing on precision medicine and non-invasive assessment.

✅ In May 2025, Mitsubishi Tanabe Pharma partnered with hospitals to validate AI-assisted imaging diagnostics for liver fibrosis staging, improving patient stratification and treatment monitoring.

☛ Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Landscape:

Allergan plc., Pfizer Inc, Gilead Sciences, Inc., Genfit SA, Novartis AG, Intercepts Pharmaceuticals, Cadila Healthcare Ltd, Novo Nordisk, Raptor Pharmaceutical Corp. and Galmed Pharmaceuticals Ltd.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?Ranjith

☛ Segments Covered in the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market:

By Therapeutics: Ocaliva | Elafibranor | Cenicriviroc | Selonsertib | Others

By Diagnostics: Imaging Techniques | Diagnostic Tests | Biopsy

By Sales Channel: Hospital Pharmacy | Online Channel | Retail Channel

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?Ranjith

☛ Regional Analysis for Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.